Gluetacs Therapeutics (www.gluetacs.com), a pioneering biotech company located in the innovative Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, is making significant strides in the field of targeted protein degradation, both in molecular glue (GLUE) and bifunctional degrader (GLUETAC). As a member of the Lingang Cambridge Network, Gluetacs is committed to advancing its cutting-edge research and development initiatives, particularly in the context of global expansion.
Company Overview
Founded in February 2020 by a team of scientists with extensive expertise in target protein degradation, Gluetacs began operations in March 2021. The company has developed a proprietary GlueTacs® platform, which includes both GLUE degrader and GLUETAC degrader technologies. With approximately 100 patents filed, Gluetacs has established a unique technical route and development strategy that sets it apart in the biotech landscape.
Comprehensive R&D Capabilities
Gluetacs Therapeutics has built a robust drug research and development system that includes:
- Multi-dimensional Phenotype Screening Platform
- Artificial Intelligence Aided Drug Design and Screening Platform
- Pharmacokinetics Screening Platform
- Multiomics and Data Mining Platform
- In Vivo Drug Pharmacology Evaluation Platform
- Safety Evaluation Platform
These platforms enable Gluetacs to conduct thorough and efficient drug discovery processes and has established a neo-substrate library for molecular glue pipeline development.
Clinical Advancements and North American Presence
Since its operational launch, Gluetacs has successfully advanced two drug candidates into Phase I clinical trials, showcasing the effectiveness of its GlueTacs® platform in rapidly discovering viable drug candidates. Notably, Gluetacs is already present in the North American market, where it has begun establishing its footprint.
Strategic Expansion into the UK Market
Recognising the potential for growth, Gluetacs is keen to expand its operations into the UK market. This strategic move aims to leverage the region's robust biotech ecosystem and regulatory frameworks to further enhance its research capabilities and commercial reach.
Recent Research Breakthroughs
In collaboration with Tan Wenfu's lab at Fudan University, Gluetacs recently published significant findings in the prestigious journal Biochemical Pharmacology. The study highlights SIAIS361034, a novel PROTAC degrader that selectively targets and degrades the BCL-xL protein in liver cancer cells. This compound, when combined with sorafenib, demonstrates enhanced safety and potent antitumor effects against hepatocellular carcinoma. Key insights from this research include:
- High expression levels of BCL-xL are correlated with poor prognosis in liver cancer patients.
- The combination of SIAIS361034 and sorafenib synergistically inhibits liver cancer cell proliferation while sparing normal liver cells from significant toxicity.
- PROTAC compounds targeting BCL-xL show superior antitumor activity compared to traditional small molecule inhibitors.
Conclusion
Gluetacs Therapeutics exemplifies innovation in the biotechnology sector, particularly within targeted protein degradation. With its established presence in North America and plans for expansion into the UK and EU markets, Gluetacs is strategically positioned to contribute significantly to global cancer treatment advancements. The company's commitment to developing effective therapies reflects its potential for both academic valuation and commercial success as it continues to grow within these key markets.
Image: Dr Yang Xiaobao, founder of Gluetacs Therapeutics, leading groundbreaking biotech innovations from Shanghai Lingang.
